RxDoctor Payments Data

Shanon Jernigan, MD

Family Medicine · Chelsea, ALNPI 1225139959

Payments from drug & device makers

$2,216in general payments, 2019–2025

Across 128 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$416
  • Esperion Therapeutics, Inc.$358
  • Novo Nordisk$341
  • AbbVie$301
  • Boehringer Ingelheim$278
  • Takeda Pharmaceuticals U.S.A., Inc.$84
  • plus $438 from 15 others

What the payments were for

  • Food & beverage$2,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,216 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$28,280
Medicare patients
130
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$42,454
JardianceEmpagliflozin23$25,934
TrulicityDulaglutide15$14,746
EliquisApixaban13$11,457
Rosuvastatin Calcium23$893
Olmesartan Medoxomil12$844
Atorvastatin Calcium63$761
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide32$564
Simvastatin24$435
Hydroxyzine Hcl11$399
Losartan Potassium26$397
Clonazepam65$364
Metformin Hcl30$351
Quetiapine Fumarate16$328
Amlodipine Besylate52$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$341$42,45449 claims
Boehringer IngelheimJardiance$278$25,93423 claims
Lilly USA, LLCTrulicity$416$14,74615 claims
PfizerEliquis$29$11,45713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Chelsea

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →